Legislative Activity

The Dismantle Iran's Proxy Act of 2025 redesignates Ansarallah as a foreign terrorist organization, imposing sanctions and requiring a strategy to restore freedom of navigation in key waterways. It mandates a report on obstacles to humanitarian aid in Yemen under Ansarallah's control and requires the president to determine if Abdul Malik al-Houthi, Abd al-Khaliq Badr al-Din al-Houthi, and Abdullah Yahya al-Hakim are officials, agents, or affiliates of Ansarallah.

The "Advancing FASD Research, Services and Prevention Act" aims to enhance support for individuals and families affected by Fetal Alcohol Spectrum Disorders (FASD) through increased research, prevention, and service programs. This act amends the Public Health Service Act to expand training, integrate a case definition for FASD, and build state and tribal capacity for identification, treatment, and support. It also establishes Fetal Alcohol Spectrum Disorders Centers for Excellence to expand diagnostic capacity, develop public awareness campaigns, and serve as clearinghouses for evidence-based resources. Finally, the act authorizes appropriations for fiscal years 2025 through 2029 to carry out these provisions and requires a report on efforts to advance public awareness and identify best practices related to FASD.

The "Miracle on Ice Congressional Gold Medal Act" authorizes the creation of three Congressional Gold Medals to honor the 1980 U.S. Olympic Men's Ice Hockey Team and their historic "Miracle on Ice" victory. These medals will be given to the Lake Placid Olympic Center, the United States Hockey Hall of Fame Museum, and the United States Olympic Paralympic Museum for public display. The Act also allows for the creation and sale of bronze duplicates to fund the medal production.

The "Supporting All Producers Act" or "SAP Act" amends the Agricultural Act of 2014, requiring the Secretary of Agriculture to consult with maple industry stakeholders to gather input on research and education priorities before issuing grant applications for the Acer Access and Development Program. It also mandates the Secretary to consider the information provided during these consultations when awarding grants and extends the Acer Access and Development Program's authorization through 2030.

The "Skinny Labels, Big Savings Act" aims to reduce drug costs by clarifying that generic drug manufacturers are not infringing on patents when seeking FDA approval for a use of a drug that is no longer covered by patent ("skinny label"). The bill amends patent law to create a safe harbor for generic drug manufacturers who seek FDA approval for a drug with a label that excludes any uses still covered by patents. This exemption extends to the promotion and marketing of the drug, as long as it does not reference the patented condition of use. The bill also includes similar provisions for biosimilar biological products.